Founded in 2012, DelphX is a technology and financial services company
DelphX is a technology and financial services company focused on bringing new and exciting alternatives to structured product and credit markets.
Recent Media Updates
DelphX Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - September 9, 2022) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) ("DelphX") announced that its Board of Directors has approved the grant of 1,500,000 stock options (the "Options") to eligible...
DelphX Secures CAD$675,600 Over-Subscribed Private Placement, Priced at a Premium to Market; New Funding Bolsters Balance Sheet Ahead of Planned Market Expansion
Toronto, Ontario--(Newsfile Corp. - August 25, 2022) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) ("DelphX"), a leader in the development of new classes of structured products for the fixed income market, announced today a non-brokered...
DelphX Announces Amicable Resolution of Issues with Larry Fondren
Toronto, Ontario--(Newsfile Corp. - July 12, 2022) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) ("DelphX") is pleased to announce that it is again aligned with its founder and largest single stakeholder, Larry Fondren. All previous issues...
DelphX Completes First CPO and CRN Issuance; Introduces Revolutionary Yield and Risk Tools for the Global Bond Market
TORONTO, June 9, 2022 /CNW/ - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) ("DelphX") is pleased to announce the first issuance of its proprietary Collateralized Put Options (CPOs) and Collateralized Reference Notes (CRNs),...
DelphX Announces Non-Brokered Private Placement of Units
Toronto, Ontario--(Newsfile Corp. - May 11, 2022) - DelphX Capital Markets Inc.(TSXV: DELX) (OTCQB: DPXCF) ("DelphX") announces that it has closed a private placement (the "Offering") of 4,982,727 units (the "Units") at a subscription price of C$0.22 per...
DelphX Grants Stock Options
Toronto, Ontario–(Newsfile Corp. – April 7, 2022) – DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) (“DelphX“) announced that its Board of Directors has approved the grant of 1,200,000 stock options (the “Options“) to eligible participants under...
View the Whitepaper on Credit Rating Securities
Focused on bringing new and exciting alternatives to structured product and credit markets
Through its special purpose vehicle Quantem, DelphX enables fixed-income dealers to offer new private placement securities that optimally transfer and diffuse credit risk, while allowing the enhancement of yield.
Market Cap Feb 18, 2023
LISTED SHARES OUT
Total Addressable Market
Upgrading the world's credit markets
DelphX provides Dealers with the ability to provide their client with a new product solution for either reducing credit exposure or enhancing yield.
Creating the Next Generation of Credit Products and Technologies
Massive Transformative Purpose
DelphX is committed to transforming credit markets by increasing access to efficient, transparent and cost effective hedging strategies and increased yields with no counterparty risks:
Provides a standardized facility to issue recognized and transparent securities fully collateralized by US Treasuries, eliminating counterparty risk.
Provides an additional vehicle for yield enhancement with improved underlying risk profiles at lower costs of capitalization – without increasing derivatives exposure.
while also giving existing participants who are seeking risk protection / peculation a cost-efficient alternative to CDS.
A Global Challenge
For over a decade, credit investors have endured a prolonged decline in investment yields. At the same time, the Credit Default Swap (CDS) market has shrunk materially:
FROM OVER
$50 Trillion
TO UNDER
The environment has been particularly vexing for life insurers and pension funds holding liabilities that were priced using assumed investment returns that are higher than can be currently achieved
THIS NEED FOR HIGHER YIELD HAS, IN TURN, CAUSED MANY CREDIT INVESTORS TO ASSUME GREATER LOSS EXPOSURE – RESULTING IN INCREASINGLY HAZARDOUS RISK/YIELD RATIOS.